acute coronary syndromes
Conditions
Interventions
Patients with acute coronary syndrome:Patients were administered 300mg loading dose of clopidogrel before PCI and received a 75-mg/d maintenance dosage of clopidogrel and 100 mg/d of aspirin for a yea
Sponsors
Institute of Clinical Pharmacology, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. diagnosed with acute coronary syndrome (medium to high risk) and schduled for primary PCI; 2. received combined therapy with aspirin and clopidogrel at least for 12 months after PCI; 3. male or non pregnant women aged 18-80 years old; 4. signed informed consent and agree to follow the requirements of study.
Exclusion criteria
Exclusion criteria: 1. Cardiogenic shock at the time of randomization; 2. Refractory ventricular arrhythmias; 3. New York Heart Association class IV congestive heart failure; 4. Fibrin-specific fibrinolytic therapy less than 24 h before randomization; 5. Non-fibrin-specific fibrinolytic therapy less than 48 h before randomization; 6. Active internal bleeding or history of bleeding diathesis; 7. Clinical findings, in the judgment of the investigator, associated with an increased risk of bleeding; 8. Any of the following: a) History of hemorrhagic stroke; b) Intracranial neoplasm, arteriovenous malformation, or aneurysm; c) Ischemic stroke within 3 months prior to screening; 9. International normalized ratio known to be greater than 1.5 at the time of screening; 10. Platelet count of less than 100000/mm3 at the time of screening; 11. Anemia (hemoglobin <10 g/dL) at the time of screening; 12. Oral anticoagulation or other antiplatelet therapy that cannot be safely discontinued for the duration of the study; 13. Daily treatment with nonsteroidal antiinflammatory drugs or cyclooxygenase-2 inhibitors; 14. Women who are known to be pregnant, have given birth within the past 90 d, or are breast-feeding; 15. Known severe hepatic dysfunction; 16. Any condition associated with poor treatment compliance, including alcoholism, mental illness, or drug dependence; 17. Intolerance of or allergy to aspirin or ticagrelor; 18. May be unable to cooperate with protocol requirements and follow-up procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiovascular death;nonfatal myocardial infarction;nonfatal stroke;urgent target vessel revascularization;stent thrombosis;Platelet aggregation;VASP-P; | — |
Countries
China
Contacts
Public ContactChen Xiao-Ping
Outcome results
None listed